Jack Bendheim - 10 Feb 2026 Form 4 Insider Report for PHIBRO ANIMAL HEALTH CORP (PAHC)

Reporting relationship: President and CEO, Director, 10%+ Owner
Issuer ticker: PAHC
Reported as of: 10 Feb 2026
Net transaction value: -$3,737,711
SEC form: 4
Accepted by SEC: 11 Feb 2026, 18:27:20 UTC
Prior SEC filing: 09 Feb 2026
Next SEC filing: 18 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Judith Weinstein, as Attorney-in-Fact for Jack Bendheim

Key filing fact

Jack Bendheim filed Form 4 for PHIBRO ANIMAL HEALTH CORP (PAHC) on 11 Feb 2026.

Key facts

This page summarizes Jack Bendheim's Form 4 filing for PHIBRO ANIMAL HEALTH CORP (PAHC).
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 11 Feb 2026, 18:27.

Change

Previous filing in this sequence was filed on 09 Feb 2026.
Current net transaction value: -$3,737,711.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001241560 Primary reporting owner

BENDHEIM JACK

Relationship: President and CEO, Director, 10%+ Owner
Address: 300 FRANK W. BURR BLVD., STE 21, TEANECK
Signature: /s/ Judith Weinstein, as Attorney-in-Fact for Jack Bendheim
Signature date: 11 Feb 2026

CIK 0001601607

BFI Co., LLC

Relationship: 10%+ Owner
Address: 300 FRANK W. BURR BLVD., STE 21, TEANECK
Signature: /s/ Judith Weinstein, as Attorney-in-Fact for BFI Co., LLC
Signature date: 11 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PAHC transaction

Class A Common Stock

Sale

Transaction value: $2,639,271
Shares: -50,994
Change %: -41%
Price: $51.76
Shares after: 71,964
Date: 10 Feb 2026
Ownership: See
Footnotes: F1, F2, F3

PAHC transaction

Class A Common Stock

Sale

Transaction value: $366,254
Shares: -7,020
Change %: -9.8%
Price: $52.17
Shares after: 64,944
Date: 10 Feb 2026
Ownership: See
Footnotes: F1, F3, F4

PAHC transaction

Class A Common Stock

Sale

Transaction value: $719,969
Shares: -13,950
Change %: -21%
Price: $51.61
Shares after: 50,994
Date: 11 Feb 2026
Ownership: See
Footnotes: F1, F3, F5

PAHC transaction

Class A Common Stock

Sale

Transaction value: $12,217
Shares: -234
Change %: -0.46%
Price: $52.21
Shares after: 50,760
Date: 11 Feb 2026
Ownership: See
Footnotes: F1, F3, F6

PAHC holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 16,840
Date: 10 Feb 2026
Ownership: Direct
Footnotes: F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 7 footnotes

Footnote F1

The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

Footnote F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.10 to $52.09. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4, 5 and 6.

Footnote F3

The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Footnote F4

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.10 to $52.30.

Footnote F5

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.11 to $52.04.

Footnote F6

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.205 to $52.21.

Footnote F7

The reported securities are directly held by Jack Bendheim.